Real-time Estimate
Cboe BZX
11:59:10 2024-05-17 am EDT
5-day change
1st Jan Change
1.03
USD
-0.96%
+13.33%
-4.67%
MiNK Therapeutics, Inc. has completed an IPO in the amount of $40.000008 million.
October 14, 2021 at 12:00 am EDT
MiNK Therapeutics, Inc. has completed an IPO in the amount of $40.000008 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 3,333,334
PriceRange: $12
Discount Per Security: $0.84
Transcript : MiNK Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 14
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 14
CI
MiNK Therapeutics, Inc. announced that it has received $5.8 million in funding
May. 13
CI
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures
May. 13
MT
MiNK Therapeutics, Inc. announced that it expects to receive $5.8 million in funding
May. 12
CI
Transcript : MiNK Therapeutics, Inc., Q4 2023 Earnings Call, Mar 21, 2024
Mar. 21
MiNK Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Mar. 21
CI
MiNK Therapeutics, Inc. Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
Mar. 06
CI
MiNK Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study for agenT-797 in Second Line Gastroesophageal Cancer
Feb. 14
CI
MiNK Therapeutics, Inc. announced that it has received $5 million in funding from Agenus Inc.
Feb. 11
CI
Mink Therapeutics' Agent-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
Feb. 06
CI
MiNK?s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
Jan. 30
CI
Transcript : MiNK Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Nov. 09
MiNK Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 09
CI
MiNK Therapeutics, Inc. Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
Nov. 03
CI
MiNK Therapeutics, Inc. Announces Resignation of as Director
23-10-17
CI
MiNK Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-10
CI
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell Microcap Value Index
23-06-23
CI
MiNK Therapeutics, Inc.(NasdaqCM:INKT) added to Russell 3000E Value Index
23-06-23
CI
MiNK Therapeutics Says Cell Product Candidate MiNK-215 Showed 'Potent Anti-Tumor Activity' in Preclinical Trial
23-05-18
MT
HC Wainwright Adjusts MiNK Therapeutics Price Target to $10 From $7, Maintains Buy Rating
23-05-12
MT
MiNK Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-11
CI
Transcript : MiNK Therapeutics, Inc., Q1 2023 Earnings Call, May 11, 2023
23-05-11
Agenus Inc. spin-off 14.5% stake in MiNK Therapeutics, Inc. for $9.1 million.
23-04-30
CI
Evercore ISI Adjusts MiNK Therapeutics' Price Target to $3 From $4, Keeps Outperform Rating
23-03-22
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. Its platform is designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. Its engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen, and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
More about the company
Last Close Price
1.04
USD
Average target price
8
USD
Spread / Average Target
+669.23%
Consensus
1st Jan change
Capi.
-4.67% 36.09M +33.44% 50.85B +0.79% 42.82B +49.62% 42.03B -4.96% 29.55B +10.93% 26.11B -21.66% 19.13B +9.19% 13.05B +27.06% 12.16B +23.96% 12.08B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1